Literature DB >> 12142379

Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry.

Christina V Obiezu1, Antoninus Soosaipillai, Klaus Jung, Carsten Stephan, Andreas Scorilas, David H C Howarth, Eleftherios P Diamandis.   

Abstract

BACKGROUND: Human kallikrein 4 (gene, KLK4; protein, hK4), a recently discovered member of the kallikrein gene family, shares many characteristics with prostate-specific antigen, the best available marker for prostate cancer. Because the protein has not been detected in any human tissue, we attempted to develop immunologic methods for hK4 analysis and use them to detect hK4 in healthy and cancerous tissue extracts and biological fluids.
METHODS: We extracted total RNA from 20 pairs of matched (healthy-cancer) prostate tissue samples. KLK4 cDNA was amplified by reverse transcription-PCR (RT-PCR) and cloned in a pPICZalphaA expression vector. We then transformed the construct product into Pichia pastoris yeast strains and induced secreted recombinant protein production by addition of methanol. We purified the recombinant protein by nickel ion-affinity chromatography and used it as an immunogen in rabbits and mice to generate polyclonal anti-hK4 antibodies. These antibodies were used to develop a sandwich-type immunoassay suitable for hK4 quantification in biological fluids and tissue extracts.
RESULTS: The immunoassay had a detection limit of 0.1 microg/L. We detected hK4 in 10 of 21 matched (healthy-cancer) prostate tissues, and hK4 was frequently higher in healthy tissues. In one matched-sample pair, the hK4 content was relatively high in both the healthy [4.62 microg/g of total protein (TP)] and the cancerous (1.22 microg/g of TP) prostate tissue. Among tissue extracts, we found the highest concentrations of hK4 in healthy (0.0-4.62 microg/g of TP) and cancerous (0.0-1.72 microg/g of TP) prostatic extracts and in placental extracts (0.0-0.05 microg/g of TP). We also detected traces of hK4 protein immunoreactivity in amniotic fluid (<0.1-0.6 microg/L), human breast milk (<0.1-0.75 microg/L), and seminal plasma (0.2-0.9 microg/L). Immunohistochemical studies showed cytoplasmic staining for hK4 protein in both malignant and benign epithelial cells of the prostate. However, we did not detect hK4 in cerebrospinal fluid, healthy and cancerous ovarian tissue extracts, and many other human tissue extracts.
CONCLUSIONS: hK4 protein is present in some prostatic tissue extracts but at relatively low concentrations, although KLK4 mRNA is readily detectable by RT-PCR. We propose that the protein either is not synthesized efficiently or is degraded very quickly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142379

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

Review 1.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

2.  Expression of kallikrein-related peptidase 4 in dental and non-dental tissues.

Authors:  James P Simmer; Amelia S Richardson; Charles E Smith; Yuanyuan Hu; Jan C-C Hu
Journal:  Eur J Oral Sci       Date:  2011-12       Impact factor: 2.612

3.  Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.

Authors:  Valérie Gratio; Nathalie Beaufort; Lina Seiz; Josefine Maier; G Duke Virca; Mekdes Debela; Nicolai Grebenchtchikov; Viktor Magdolen; Dalila Darmoul
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

4.  Hypomaturation enamel defects in Klk4 knockout/LacZ knockin mice.

Authors:  James P Simmer; Yuanyuan Hu; Rangsiyakorn Lertlam; Yasuo Yamakoshi; Jan C-C Hu
Journal:  J Biol Chem       Date:  2009-05-06       Impact factor: 5.157

Review 5.  Emerging PSA-based tests to improve screening.

Authors:  Richard J Bryant; Hans Lilja
Journal:  Urol Clin North Am       Date:  2014-02-26       Impact factor: 2.241

6.  Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays.

Authors:  Theano D Karakosta; Antoninus Soosaipillai; Eleftherios P Diamandis; Ihor Batruch; Andrei P Drabovich
Journal:  Mol Cell Proteomics       Date:  2016-07-01       Impact factor: 5.911

7.  Genetic association of the KLK4 locus with risk of prostate cancer.

Authors:  Felicity Lose; Srilakshmi Srinivasan; Tracy O'Mara; Louise Marquart; Suzanne Chambers; Robert A Gardiner; Joanne F Aitken; Amanda B Spurdle; Jyotsna Batra; Judith A Clements
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

8.  KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer.

Authors:  Brian W-C Tse; Thomas Kryza; Mei-Chun Yeh; Ying Dong; Kamil A Sokolowski; Carina Walpole; Tobias Dreyer; Johanna Felber; Jonathan Harris; Viktor Magdolen; Pamela J Russell; Judith A Clements
Journal:  Cancers (Basel)       Date:  2020-11-24       Impact factor: 6.639

9.  The solution structure of the kallikrein-related peptidases inhibitor SPINK6.

Authors:  Sascha Jung; Jan Fischer; Björn Spudy; Tim Kerkow; Frank D Sönnichsen; Li Xue; Alexandre M J J Bonvin; Peter Goettig; Viktor Magdolen; Ulf Meyer-Hoffert; Joachim Grötzinger
Journal:  Biochem Biophys Res Commun       Date:  2016-01-30       Impact factor: 3.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.